Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the Impact of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age
This study is currently recruiting participants.
Study NCT00514891   Information provided by Bandim Health Project
First Received: August 8, 2007   Last Updated: November 6, 2008   History of Changes

August 8, 2007
November 6, 2008
August 2007
 
Mortality, morbidity
Same as current
Complete list of historical versions of study NCT00514891 on ClinicalTrials.gov Archive Site
Growth, Vitamin A status, Immunology
Same as current
 
Evaluation of the Impact of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age
Evaluation of the Impact on Mortality and Morbidity of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age

High-dose vitamin A to children above 6 months of age reduces all-cause mortality by 23-30%. The WHO recommends vitamin A supplementation (VAS) with the first vaccine after 6 months of age. However, the effect of providing VAS with vaccines has never been investigated. We have hypothesised that the effect of VAS depends on the immune stimulus at the time of supplementation. Hence, the effect might vary depending on which type of vaccine it is given with. In particular, we hypothesised that VAS might be beneficial when given with measles vaccine but not when given with DTP vaccine. Normally the first vaccine after 6 months of age would be a measles vaccine, but many children come late for their DTP vaccinations and receive DTP alone or together with measles vaccine. Hence, it is important to study whether the effect of VAS is the same irrespective of the vaccine(s) administered at the same time.

Guinea-Bissau has not yet implemented the WHO vitamin A policy of providing VAS with vaccines, but plans to do so within the next years. Together with the Ministry of Health in Guinea-Bissau, the Bandim Health Project (BHP) in Guinea-Bissau will investigate the effect on mortality and morbidity of implementing the WHO vitamin A policy in Guinea-Bissau. This will be done in a large randomised trial.

BHP has a demographic surveillance system (DSS) which has followed a population of now more than 150,000 individuals for almost 30 years. Children will be randomised to receive VAS or placebo with their first vaccine after 6 months of age, and will be followed through the DSS to assess mortality and morbidity. Based on previous observations, the effects of VAS might differ according to sex and season. The interaction between VAS, sex, and season will also be studied in the present trial. By identifying situations where VAS may be beneficial, ineffective, or even harmful the study may contribute importantly to optimising the VAS policy for low-income countries.

 
Phase IV
Interventional
Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
  • Mortality
  • Morbidity
Biological: Vitamin A
  • Active Comparator: Vitamin A supplementation
  • Placebo Comparator: Placebo
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
 
 
 

Inclusion Criteria:

  • Urban area: 6-17-month-old children, presenting for vaccination at a health centre in the study area.
  • Rural area: 6-23-month-old children who are missing one or more routine vaccinations when visited by our mobile team.

Exclusion Criteria:

  • Normally applied contraindications for receiving vaccinations, including high fever.
  • VAS within last month.
Both
6 Months to 23 Months
 
Contact: Ane B Fisker, MD +245 201489 a.fisker@bandim.org
Contact: Christina Rasmussen, MSc +45 32683162 crn@ssi.dk
Guinea-Bissau
 
NCT00514891
 
CVK-2006-7041-99
Bandim Health Project
  • Ministry of Health, Guinea-Bissau
  • University of Aarhus
Principal Investigator: Christine S Benn, MD, PhD Bandim Health Project, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
Study Director: Peter Aaby, Dr.Med. Bandim Health Project, Apartado 861, 1004 Bissau Codex, Guinea-Bissau
Bandim Health Project
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP